- Navrogen Signs Commercial Evaluation License Agreement with The National Cancer Institute to Develop Next-Generation Therapies for Immunosuppressed CancersJuly 1, 2021Navrogen, Inc. and the National Cancer Institute (NCI), part of the National Institutes of Health, have established a research collaboration aimed at testing mesothelin-targeting therapies for the treatment of cancers where humoral immunity is suppressed. [read more]
- Navrogen Establishes Research Collaboration with The National Cancer Institute to Test Mesothelin-Targeting Therapies for Cancers Affected by Humoral Immuno-Oncology FactorsJanuary 11, 2021Navrogen, Inc. and the National Cancer Institute (NCI), part of the National Institutes of Health, have established a research collaboration aimed at testing mesothelin-targeting therapies for the treatment of cancers where humoral immunity is suppressed. [read more]
- Navrogen Signs Commercial License Agreement with The National Cancer Institute to Develop Next-Generation Therapies for Immuno-suppressed CancersSeptember 29, 2020Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announced today that it has signed a license agreement with the National Cancer Institute (NCI) for the commercialization of mesothelin-targeting agents. [read more]
- Navrogen Awarded National Cancer Institute Grant to Develop Next-Generation Rituximab with Enhanced Therapeutic EffectsSeptember 14, 2020Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announced today that it has been awarded a National Cancer Institute (NCI) R03 Grant to support its NAV-006 program involving the development of a next-generation rituximab that is refractory to the immuno-suppressive effects of the tumor microenvironment. [read more]
- Navrogen and Levena Announce Collaboration to Develop Antibody Drug Conjugates to Treat Humoral Immuno-Suppressed CancersFebruary 4, 2020Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, and Levena Biopharma, a company specialized in developing antibody drug conjugates (ADCs), announced today the expanded collaboration to develop ADCs targeting humoral immuno-suppressed cancers. [read more]
- Navrogen Opens R&D Operations at Cheyney UniversityJanuary 31, 2020Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announced the opening of its R&D operations at the Cheyney University science center located in Chester County, PA. The move enables the company to expand its proprietary Humoral Immuno Oncology (HIO) technology discovery efforts. [read more]
- Navrogen Inc. and Lonza Sign Agreement to Use Lonza’S GS Gene Expression System® for Navrogen’s Anti-HIO Targeting AgentsNovember 20, 2019Navrogen Inc. and Lonza Pharma & Biotech announced today that they have entered a licensing agreement for the production of Navrogen's biotherapeutics using Lonza’s GS Xceed Expression System. Navrogen recently announced funding to develop biotherapeutics targeting Humoral Immuno-Oncology (HIO) factors to reverse their inhibitory activity against the pharmacologic effects of antibody-based therapies. [read more]
- Navrogen Enters into CRADA with the U.S. National Cancer Institute to Develop Agents to Overcome Tumor-Mediated ImmunosuppressionOctober 1, 2019Navrogen, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI). The CRADA is focused on advancing antibody-based experimental medicines to targets associated with tumor-mediated immunosuppression. [read more]
- Navrogen Announces the Closing of $3.2M Funding to Support its Humoral Immuno-Oncology Platform Discovery Technologies and Preclinical PipelineSeptember 17, 2019Navrogen, Inc. announced today that it has raised $3.2M in convertible note financing to support its operations, Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities. The financing was led by Ben Franklin Technology Partners of South Eastern Pennsylvania and a number of private investors. [read more]